The burgeoning landscape of innovative treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://ianusvk308199.wikicorrespondence.com/5957310/retatrutide_vs_tirzepatide_a_comparative_analysis